Toggle navigation
Home
Search
Services
Blog
Contact
About
OBl-1 - 201: Dosing regimen, cogential hemophilia, non-life threatening bleeding
Bergman, Garrett E.
Octagen Corporation, Blue Bell, PA, United States
Search 11 grants from Garrett Bergman
Search grants from Octagen Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Effects of Foxp3-Induced Regulatory T Cells on GVHD and GVT Activity
Transcription termination and antitermination in E.coli
Exercise as Preventive Medicine in the Aging Process
Characterization of HIV Infection in Peripheral Blood Mononuclear Cells
Standardized Reproducible Spinal Cord Injury Model
Recently added grants:
In Vivo Model and Histology Core
Endplate Sensory Innervations for LBP
PTH Attenuation of Spinal Degeneration During Aging PI Janet Crane
Senescence of Pre-Osteoclasts in Non-Traumatic OA
Modeling Photoreceptor Migration in Biomimetic Microenvironments to Optimize Transplantation
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44HL064497-04
Application #
7149838
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2005-08-01
Project End
2008-07-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
Octagen Corporation
Department
Type
DUNS #
052982852
City
Blue Bell
State
PA
Country
United States
Zip Code
19422
Related projects
Comments
Be the first to comment on Garrett Bergman's grant